This class of compounds was originally discovered through high throughput screening. The target of this class was determined to be inhibition of tryptophan biosynthesis in Mycobacterium tuberculosis. If development of this calls is successful, it could identify a new target for TB drugs. Prior TB Alliance work demonstrated in vivo efficacy of some analogues in this series. The current program aims to improve their properties as drugs.